MoneyWorks4Me

Zydus Lifesciences informs about press release

04 May 2024 Evaluate

Zydus Lifesciences has informed that it enclosed a copy of press release dated May 4, 2024 titled ‘Sentynl Therapeutics announces global acquisition of Zokinvy® (Lonafarnib) for treatment of Hutchinson-Gilford Progeria Syndrome from Eiger Biopharmaceuticals’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1135.35 -14.65 (-1.27%)
09-Sep-2026 11:05 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1874.70
Dr. Reddys Labs. 1140.80
Cipla 1374.10
Lupin 2103.50
Zydus Lifesciences 1135.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: